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ABBREVIATIONS 
 
BM  Bone marrow 
DC  Dendritic cell 
Foxp3  Forkhead-box transcription factor p3 
GVHD  Graft-versus-host disease 
HC  Hematopoietic cell 
i.v  Intravenous 
TGF-β  Transforming growth factor-β 
Treg  Regulatory T cells; 
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ABSTRACT 
 
Immunomodulatory properties are attributed to apoptotic cells. These properties have been 
used to modulate allogeneic immune responses in experimental transplantation settings. In 
independent studies, apoptotic cell infusion has been shown to favor hematopoietic cell 
engraftment, to increase heart graft survival and to delay the lethal onset of graft-versus-host 
disease (GVHD). The goal of this review was to discuss how apoptotic cell infusion interferes 
with graft rejection or host rejection (i.e., GVHD) and to focus on the potential mediators or 
"perpetuators" involved in apoptotic cell-induced immunomodulation. Particular emphasis on 
apoptotic cell phagocytosis, TGF-β secretion and regulatory T cell induction was performed. 
Stimulating "naturally" immunosuppressive molecules (i.e., TGF-β) or immunomodulatory 
cells ("alternatively-activated" macrophages, certain DC subsets or regulatory T cells) in a 
physiological manner by using apoptotic cell infusion can be a promising way to induce 
tolerance. 
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Although the use of non specific immunosuppressive drugs has significantly reduced the 
incidence of acute graft rejection, the benefits of such therapies on chronic rejection and 
overall long-term graft survival are uncertain. Persistent excessive immunosuppression after 
therapeutic approaches of this type is associated with considerable long-term toxicity 
including increased incidence of cancers, infectious complications as well as metabolic 
diseases (e.g., diabetes, atherosclerosis, etc). Immunomodulatory approaches allowing for 
increased specificity are therefore needed. Cell-based therapy is one way of achieving 
tolerance to donor antigens. The use of donor apoptotic cell infusion has been proposed as 
an "alternative" cell-based therapy approach to induce tolerance. The mediators or 
"perpetuators" involved in the immunomodulatory properties of apoptotic cells are discussed 
in this review.  
 
Immunomodulatory properties of apoptotic cells 
Immunomodulatory properties are attributed to apoptotic cells. This is due to apoptotic cells 
themselves (1, 2) or to cells phagocyting apoptotic cells (3, 4). Professional phagocytes, 
such as macrophages (3) or certain dendritic cells (DC) subsets (4), quickly capture 
apoptotic bodies, thereby preventing both the release of harmful products from dying cells 
turning to necrosis and the associated inflammatory responses. Several mechanisms have 
been described to explain the immunomodulatory effects of apoptotic cells (5). Engulfment of 
apoptotic cells inhibits proinflammatory cytokine production by blocking NF-κB activation in 
phagocyting cells (6). Apoptotic cell uptake by phagocytes blocks also their production of the 
type 1 cytokine IL-12 (7) as well as the Th17-related cytokines, IL-17 and IL-23 (8). 
Moreover, apoptotic neutrophils and T cells may prevent inflammatory cell recruitment by 
sequestering chemokines (2). In addition, apoptotic cell death is frequently associated with 
an immunomodulatory milieu that may neutralize immune cells present in the environment of 
dying cells. Such milieu consists mainly of anti-inflammatory factors like TGF-β, IL-10, IL-1 
receptor antagonist, prostaglandin-E2 and hepatocyte growth factor (3, 9-11). These factors 
can be released by phagocytes (3) and/or by apoptotic cells themselves (1). However, the 
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immunomodulatory effects induced by apoptotic cells can be modulated or influenced by 
several factors (5, 12) [Figure 1] such as cell death-inducing agents (13), soluble factors that 
bridge apoptotic cells to phagocytes (5, 14), or ligand receptor interactions involved in 
apoptotic cell uptake (5, 15). Rapidly after the initiation of the apoptotic process, changes 
including alterations in glycosylation, charge and surface lipids occur at the cell surface of 
dying cells. The best-characterized modification is the loss of phospholipid asymmetry and 
the exposure of phosphatidylserine on the outer surface. Recently, exposure of calcireticulin 
after tumor cell death has been shown to trigger an efficient immune response against dying 
tumors (16). The route of administration and the site where apoptotic cells die may trigger 
inflammation and vigorous immune responses. This can lead to immune responses directed 
against apoptotic cell-derived antigens (Fig. 1), as mentioned above (13, 16). Thus, in order 
to use apoptotic cells as a cell therapy product, all of the latter factors, including the route of 
administration, have to be defined. Intended to induce immunomodulation, the tolerogenic 
intravenous (i.v.) route will be requisite. 
 
Use of apoptotic cell infusion in transplantation settings 
Physiological mechanisms that maintain immune homeostasis and self-tolerance have been 
exploited for a long time to induce tolerance to allografts. This is why the inhibitory effects of 
apoptotic cell infusion have been used to modulate alloreactive responses in experimental 
transplantation models (17-21) [Table 1]. In hematopoietic cell (HC) transplantation, i.v. 
apoptotic cell infusion favors allogeneic HC engraftment (17), delays the onset of lethal acute 
GVHD (18) and prevents the anti-donor humoral response (19). In solid organ transplantation 
models, donor apoptotic cell infusion increases heart graft survival (20, 21) whatever the 
timing of infusion: 7 days before heart transplantation (19) (as previously done with donor 
specific blood transfusion) or 7 days after (20). The timing of apoptotic cell infusion does not 
seem to be a critical factor in the interference of alloreactive immune responses. The next 
questions to address are how i.v. apoptotic cell infusion may interfere with alloreactive 
 7 
responses and by which mediators (and mechanisms) the immunomodulatory effects are 
propagated? 
 
Mediators involved in the immunomodulatory effects of apoptotic cells 
All three studies performed in transplantation settings (18, 20, 21) shared the requirement for 
apoptotic cell phagocytosis in a limited area (the spleen), but the nature of phagocytes 
differed. Two studies (18, 20) identified recipient macrophages as critical for the apoptotic 
cell infusion-induced immunomodulatory effects. This was attested by macrophage depletion 
before apoptotic cell infusion using gadolinium chloride (20) or clodronate-loaded liposomes 
(18). Conversely, host CD8+ DC allowed prolonged graft survival when apoptotic cells were 
infused after heart transplantation, as shown by adoptive transfer experiments (21). 
However, a direct role of DC was excluded in Ref.18 where despite efficient depletion of 
CD11chigh DC in a transgenic mouse model, apoptotic cell infusion still favored HC 
engraftment. The read out used (depletion (18, 20) versus adoptive transfer, Ref.21) may 
influence the result. Nevertheless, it makes sense to identify different phagocytes depending 
on the transplantation model used: heart (21) versus HC (18). Macrophages and DC diverge 
in their antigen presentation capacity due to their lysosomal protease content (22). 
Macrophages rapidly degrade internalized antigens without presenting them, while DC 
exhibit limited lysosomal degradation capacity (22) favoring donor alloantigen presentation. A 
restricted donor-specific effect related to donor apoptotic cell phagocytosis by DC and 
subsequent donor alloantigen presentation may account for prolonged heart graft survival 
(21). Donor apoptotic cell-loaded DC may migrate to the thymus to perform alloantigen-
specific T cell deletion. In HC transplantation, apoptotic cell phagocytosis by macrophages 
(18) may lead to a non-specific anti-inflammatory effect associated with TGF-β production 
(19, see below), independent of donor alloantigen presentation. Indeed, HC engraftment is 
favored whatever the origin (donor/recipient/other) of apoptotic cells (17, 19). The 
subsequent anti-inflammatory effect related to TGF-β secretion may neutralize host immune 
cells to allow HC engraftment and reduce the cytokine storm responsible for GVHD initiation. 
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To reconcile data obtained from different transplantation models (17, 19), an alternative 
explanation would be that both macrophages and DC are necessary for apoptotic cell-
induced engraftment. In this scenario, anti-inflammatory cytokines produced by macrophages 
after phagocytosis (i.e., TGF-β) may induce DC to present alloantigens from apoptotic cells 
in an inefficient manner. This may explain why donor apoptotic cell-loaded DC infusion after 
heart transplantation induces an initial proliferation of alloreactive T cells followed by their 
deletion (21). This hypothesis is currently under investigation. 
Another mediator involved in the immunomodulatory effects of apoptotic cell infusion in 
transplantation settings is TGF-β. Increased TGF-β transcripts were detected on day 3 post-
transplantation in the spleen of mice that had received apoptotic spleen cells simultaneously 
with bone marrow (BM) grafts (Figure 2). Neutralization of this cytokine abrogates the effects 
of i.v. apoptotic cell infusion on BM engraftment (19) and the prevention of anti-donor 
alloimmunization (19). Indeed, i.v. apoptotic cell infusion given simultaneously with 
hematopoietic allografts prevents anti-BM donor immunization even in mice rejecting their 
graft (19). This alteration of allogeneic humoral responses was also observed when donor 
apoptotic cells were infused after heart transplantation (21). TGF-β is implicated in the 
conversion of naive CD4+ CD25- T cells into regulatory T cells (Treg) (23); analysis of Treg 
after apoptotic cell infusion was thus performed. Foxp3+ Treg were identified as propagating 
the effect of i.v. apoptotic cell infusion both in heart (21) and BM (18) transplantation models. 
In the BM transplantation model, the involvement of TGF-β secretion and splenic 
macrophages in the induction of Treg was demonstrated (18). Indeed, TGF-β neutralization 
or clodroante-loaded liposome infusion blocked Treg expansion induced by i.v. apoptotic cell 
infusion (18). In this model, a direct link between macrophage and TGF-β secretion has yet 
to be demonstrated. Interleukin-10 dependent-Treg induction after infusion of syngeneic 
splenocytes rendered apoptotic by photopheresis has also been reported (24). Interestingly, 
Treg induction after random blood product transfusion has been reported previously (25) and 
nonspecific immunomodulatory effects of preoperative blood product transfusion has been 
proposed to be related to the presence of apoptotic leukocytes in stored blood products (26). 
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Treg induction after blood cell apoptosis –a frequent phenomenon, mimicked by i.v. infusion 
of apoptotic cells may constitute an additional mechanism to prevent autoimmunity that 
could be used in transplantation. 
 
Conclusion 
In conclusion, we propose infusing apoptotic cells to interfere with graft rejection or host 
rejection (GVHD). This approach permits to stimulate "naturally" immunosuppressive 
molecule production (i.e., TGF-β) or to activate immunomodulatory cells (such as Treg and 
particular DC or macrophage subsets) in a physiological manner. Exploiting such 
mechanisms may facilitate the induction of immunological tolerance to transplants. However, 
before the possible application of such therapy to clinical transplantation, several obstacles 
need to be overcome, including the interactions of such an approach with 
immunosuppressive regimens. In the future, i.v. donor apoptotic cells may become a well-
defined cell therapy product and a substitute for the blood products formerly used in 
transfusion practice to prolong graft survival. Indeed, similitude exists between donor-specific 
blood transfusion and i.v. apoptotic leukocyte infusion including induction of Treg (25) or of 
TGF-β production (27). Some biological effects of transfusion may be related to the presence 
of apoptotic leukocytes in blood products (26). This idea of using the immunomodulatory 
properties of apoptotic cells in cell-based therapy is moving forward, since such an approach 
has also been proposed to increase cardiac muscle repair (28). 
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TABLE 1. Immunomodulatory effects of intravenous apoptotic cell infusion in 
transplantation settings: an overview. 
 
Experimental 
transplantation 
models: 
Hematopoietic 
cell engraftment 
Rat heart 
transplantation 
Graft-versus-
Host Disease 
Mouse heart 
transplantation 
Dependent on 
the origin of 
infused 
apoptotic cells: 
 
no (17,19) yes (only donor 
apoptotic cells 
prolong survival, 
[20]) 
yesa yes (only donor 
apoptotic cells 
prolong survival, 
[21]) 
Timing of 
apoptotic cell 
infusion: 
 
with the bone 
marrow graft 
(17-19) 
7 days before 
heart transplant 
(20) 
with the bone 
marrow graft 
(18) 
7 days after 
transplant (21) 
Required 
phagocytes: 
splenic host 
macrophages 
(18) 
 
host 
macrophages 
(20) 
ND splenic host 
CD8+ DC (21) 
Required 
cytokines: 
 
TGF-β (18, 19) ND ND intragraft TGF-β 
and IL-10 (21) 
Treg induction: yes, but not 
critical in the 
graft facilitating 
effects (18) 
ND yes, Treg 
participate to 
delay the onset 
of lethal GVHD 
(18) 
 
suspected, 
Foxp3+ Treg 
present in the 
graft (21) 
Inhibition of anti-
donor 
immunization: 
yes (19) in a 
TGF-β-
dependent 
manner 
ND ND yes (suppress 
systemic anti-
donor response; 
IFN-γ inhibition, 
[21]) 
aKleinclauss F, de Carvalho Bittencourt M, Saas P, unpublished results 
ND, not determined. 
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FIGURE LEGENDS 
 
FIGURE 1. Factors influencing the immune response to apoptotic cells. Several factors 
may influence the immune response to apoptotic cells. Factors involved in the activation of 
the immune response are listed on the left hand side, while those implicated in its down-
regulation are mentioned on the right hand side. This figure is modified from Ref. 12 and 
updated with recent references (see text). Abbreviations: DC: dendritic cell; Phag: 
phagocytes; Rec: receptor; CR3: Complement receptor 3; CRP: C reactive protein; SAP: 
serum amyloid P component; C1q: one of the first fractions of the complement. 
 
FIGURE 2. Early increase of TGF-β mRNA transcript after intravenous donor apoptotic 
cell infusion simultaneously with bone marrow graft. Total RNA was extracted from 
spleen of BALB/c mice grafted with 106 FVB BM (black triangles) or with 5x106 FVB apoptotic 
splenocytes (Apo C) plus 106 FVB BM (open square) using RNA extraction kit (Qiagen, 
Valencia, CA) and reverse transcribed using random hexamers and M-MLV reverse 
transcriptase (Life Technologies, Rockville, MD) to use as template for quantitative real time 
RT-PCR (QRT-PCR). QRT-PCR reactions were performed as described (18). Primers and 
dual labeled fluorescent probes were designed using Primer Express® software (Applied 
Biosystems, Forster City, CA) to be specific for RNA but not for genomic DNA. QRT-PCR 
primer pairs and related probes were as follow (sense, antisense and probe respectively). 
TGF-β: 5'-GCTCTTGTGACAGCAAAGATAACAA-3', 5'-GGTCGCCCCGACGTTT-3' and 5'-
FAM-CACGTGGAAATCAACGGGATCAGCC-TAMRA-3'; Primer pairs for GAPDH (used as 
endogenous reference)were already described (18). The relative quantity of each unknown 
sample was determined automatically with the iCycler iQ® software (Bio-Rad Laboratories, 
Marnes-la-Coquette, France), using the threshold cycle (Ct). Data were expressed as 
normalized TGF-β1 expression, which was obtained by dividing the relative quantity of TGF-
β1 mRNA for each sample by the relative quantity of GAPDH mRNA of the same sample. 
*P<0.05. 
 16 
Figure 1 
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Figure 2. 
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